Effect of infliximab on sight-threatening panuveitis in Behcet's disease
Effect of infliximab on sight-threatening panuveitis in Behcet's disease
复制标题
DOI：
10.1016/s0140-6736(01)05497-6
复制
发表时间：
2001-07-28
期刊：
影响因子：
168.9
通讯作者：
Markomichelakis, NN
中科院分区：
文献类型：
--
作者：
Sfikakis, PP;Theodossiadis, PG;Markomichelakis, NN
尽管进行了长期的免疫抑制治疗，但白塞病患者经常发生复发性眼部炎症导致的永久性视力丧失。由于肿瘤坏死因子（TNF）在白塞病中可能具有重要的致病作用，我们决定在5例复发性全葡萄膜炎患者最后一次复发时给予单次输注英夫利昔单抗（一种抗TNF的单克隆抗体）。在所有患者中，眼部炎症的缓解在前24小时内是明显的，并且在治疗后7天观察到完全抑制。未发现副作用。我们认为英夫利昔单抗是治疗白塞病中威胁视力的眼部炎症的一种快速有效的新疗法。
Permanent loss of vision resulting from relapsing ocular inflammation occurs frequently in patients with Behcet's disease, despite intensive, chronic Immunosuppressive therapy. Since tumour necrosis factor (TNF) might have an Important pathogenetic role in Behcet's disease, we decided to give a single Infusion of infliximab-a monoclonal antibody against TNF-to five patients with relapsing panuveitis, at the immediate onset of last relapse. Remission of ocular Inflammation was evident within the first 24 h, and complete suppression was seen 7 days after treatment In ail patients. No side-effects were noted. We suggest that Infliximab is a rapid and effective new therapy for sight-threatening ocular inflammation in Behcet's disease.